Therapeutic drug monitoring in the treatment of M/XDR RB

Introduction: With more than 1.6 million deaths in 2017, tuberculosis (TB) is currently the leading cause of death by a single pathogen. The WHOʼs plans to drastically reduce TB incidence and mortality by 2035 is hampered by emerging drug resistance: The management of patients with multidrug-resistant TB (MDR-TB) and especially extensively drug-resistant TB (XDR-TB) it is costly and the drug regimens often lead to adverse drug events. Acquired drug resistance (ADR) on inadequate treatment regimens is regularly observed. Therapeutic drug monitoring (TDM) can individually optimise the dosages of drugs thus reducing the risk for ADR and adverse events. We present the effect of individualised drug dosages based on TDM for a patient with advanced XDR-TB.